Cure My Disease

Don't miss your cure!

 Log in / Sign up

New yellow fever vaccine shows promise in Mid-Stage trial

NCT ID NCT05011123

Ongoing ⭐️ VACCINE ⭐️ Sponsor: Sanofi Pasteur, a Sanofi Company Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This Phase 2 study tests a new yellow fever vaccine (vYF) against the current licensed vaccine (Stamaril) in 690 healthy adults aged 18-60 in Europe and Asia. Participants receive one shot, and researchers measure immune response and safety over 5 years. The goal is to see if the new vaccine works as well as the existing one.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
yellow fever vaccine (vYF)
What this could lead to
If successful, this could provide a new, safe, and effective yellow fever vaccine option for adults, potentially improving global vaccine supply.
What could go wrong
This is a Phase 2 trial, so results are still early. The new vaccine may not prove as effective or safe as the existing licensed vaccine, Stamaril.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for YELLOW FEVER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

yellow fever prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

YELLOW FEVER

Contacts and locations

Locations

  • Investigational Site Number : 2460001

    Helsinki, 00290, Finland

  • Investigational Site Number : 2460002

    Tampere, 33100, Finland

  • Investigational Site Number : 2460003

    Turku, 20520, Finland

  • Investigational Site Number : 2500001

    Nantes, 44093, France

  • Investigational Site Number : 2500004

    Pierre-Bénite, 69495, France

  • Investigational Site Number : 2500006

    Montpellier, 34295, France

  • Investigational Site Number : 2500007

    Nîmes, 30029, France

  • Investigational Site Number : 2500008

    Lyon, 69004, France

  • Investigational Site Number : 2500009

    Paris, 75014, France

  • Investigational Site Number : 2760001

    Hamburg, 20359, Germany

  • Investigational Site Number : 2760002

    München, 80802, Germany

  • Investigational Site Number : 2760003

    Rostock, 18057, Germany

  • Investigational Site Number : 2760004

    Berlin, 10117, Germany

  • Investigational Site Number : 7020001

    Singapore, Singapore

  • Investigational Site Number : 7020002

    Singapore, 119074, Singapore

  • Investigational Site Number : 7020003

    Singapore, 169608, Singapore

  • Investigational Site Number : 7240001

    Barcelona, 08036, Spain

  • Investigational Site Number : 7240002

    Madrid, Madrid, Comunidad de, 28046, Spain

  • Investigational Site Number : 7240003

    L'Hospitalet de Llobregat, Barcelona [Barcelona], 08907, Spain

  • Investigational Site Number : 7240004

    Barcelona, Barcelona [Barcelona], 08035, Spain

  • Investigational Site Number : 7640001

    Bangkok, 10330, Thailand

  • Investigational Site Number : 7640002

    Bangkok, Thailand

  • Investigational Site Number : 7640003

    Nonthaburi, 11000, Thailand

More trials for these conditions

Other studies related to the condition(s) this trial covers.